FHL is developing a number of innovative drugs to effectively treat common diseases among the aging population, including Parkinson’s disease, Alzheimer’s disease, and Rheumatoid Arthritis. These compounds range across small molecules derived from natural plants, repurposed drugs, and nasally-administered peptides. The drugs have demonstrated robust animal proof of concept to significantly change the disease progression, not merely symptomatic relief, supported by the scientific mechanism of action. FHL is working hard with its close partners to bring these therapeutic options to human patients in highly unmet medical needs.
Forest Hills Partners Hong Kong Limited (FHL) agreed to in-license global commercial rights to a number of attractive therapeutic drug candidates that promote longevity and healthy lifestyle, including FHL CB-101, 201, 301, and 401. These multiple compounds target critical neurodegenerative and autoimmune diseases, such as Parkinson’s disease, Alzheimer’s disease, and Rheumatoid Arthritis by treating disease progression and not merely symptomatic conditions.